Advertisement


Jenny F. Seligmann, MBChB, PhD, on Colorectal Cancer: Adavosertib Compared With Active Monitoring

ESMO Congress 2021

Advertisement

Jenny F. Seligmann, MBChB, PhD, of the University of Leeds, discusses phase II findings that suggest adavosertib improved progression-free survival, compared with active monitoring, by inhibiting the WEE1 kinase in patients with RAS- and TP53-mutant metastatic colorectal cancer. In the trial, adavosertib’s activity tended to be even greater in left-sided tumors (Abstract 382O).



Related Videos

Breast Cancer
Immunotherapy

Helena M. Earl, MBBS, PhD, on HER2-Positive Early Breast Cancer: A Meta-analysis of Trastuzumab Trials

Helena M. Earl, MBBS, PhD, of the University of Cambridge, discusses an individual patient data meta-analysis of noninferiority randomized clinical trials to determine whether a duration of less than the standard of 12 months of adjuvant trastuzumab is noninferior for treatment outcomes in patients with HER2-positive early breast cancer (Abstract LBA11).

Issues in Oncology

Joseph M. Unger, PhD, on the Impact of NCI-Sponsored Treatment Trials

Joseph M. Unger, PhD, of Fred Hutchinson Cancer Research Center, discusses findings from his study of the National Cancer Institute’s Clinical Trials Network, which has conducted publicly funded cancer research for more than 50 years. The substantial gains in life years for patients with cancer, he says, supports the critical role of government-sponsored cancer research (Abstract 1503O).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Quality-of-Life Data From KEYNOTE-564 on Pembrolizumab vs Placebo

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses patient-reported outcomes for quality of life in the KEYNOTE-564 study, which previously met its primary endpoint of disease-free survival with adjuvant pembrolizumab vs placebo following surgery for renal cell carcinoma (Abstract 653O).

Breast Cancer

Gabriel N. Hortobagyi, MD, on Advanced Breast Cancer Treated With Endocrine Therapy and Ribociclib

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses results from the MONALEESA-2 trial, which showed that adding the CDK4/6 inhibitor ribociclib to first-line hormonal therapy prolongs survival by 1 year for postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer. As a result, he believes it should be considered the preferred treatment option (Abstract LBA17).

 

Breast Cancer
Immunotherapy

Javier Cortés, MD, PhD, on HER2-Positive Breast Cancer: Trastuzumab Deruxtecan vs Trastuzumab Emtansine

Javier Cortés, MD, PhD, of Barcelona’s IOB Institute of Oncology, discusses phase III data from the DESTINY-Breast03 study, which support trastuzumab deruxtecan becoming the standard of care for second-line treatment of women with HER2-positive metastatic breast cancer (Abstract LBA1).

Advertisement

Advertisement




Advertisement